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Abstract
Background
The combination pharmacotherapy of antiplatelet agents, lipid-modifiers, ACE inhibitors/
ARBs and beta-blockers are recommended by international guidelines. However, data on
effectiveness of the evidence-based combination pharmacotherapy (EBCP) is limited.
Objectives
To determine the effect of EBCP on mortality and Cardiovascular events in patients with
Coronary Heart Disease (CHD) or cerebrovascular disease.
Methods
Publications in EMBASE and Medline up to October 2018 were searched for cohort and
case-control studies on EBCP for the secondary prevention of cardiovascular disease. The
main outcomes were all-cause mortality and major cardiovascular events. Meta-analyses
were performed based on random effects models.
Results
21 studies were included. Comparing EBCP to either monotherapy or no therapy, the pooled
risk ratios were 0.60 (95% confidence interval 0.55 to 0.66) for all-cause mortality, 0.70
(0.62 to 0.79) for vascular mortality, 0.73 (0.64 to 0.83) for myocardial infarction and 0.79
(0.68 to 0.91) for cerebrovascular events. Optimal EBCP (all 4 classes of drug prescribed)
had a risk ratio for all-cause mortality of 0.50 (0.40 to 0.64). This benefit became more dilute
as the number of different classes of drug comprising EBCP was decreased—for 3 classes
of drug prescribed the risk ratio was 0.58 (0.49 to 0.69) and for 2 classes, the risk ratio was
0.67 (0.60 to 0.76).
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Conclusions
EBCP reduces the risk of all-cause mortality and cardiovascular events in patients with CHD
or cerebrovascular disease. The different classes of drugs comprising EBCP work in an
additive manner, with optimal EBCP conferring the greatest benefit.
Introduction
Cardiovascular disease (CVD) is the leading cause of mortality and morbidity worldwide. Based
on statistics from The World Health Organization (WHO), coronary heart disease (also known as
ischaemic heart disease) and stroke are the top two causes of death globally [1]. Pharmacological
therapy plays a key role in the secondary prevention of CVD. Large evidence supports drugs con-
ferring mortality benefit from several different classes: antiplatelet agents, angiotensin-converting
enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs), beta blockers and lipid-lower-
ing drugs [2–4]. These are recommended by the WHO [5] and guideline bodies including the
National Institute for Health and Care Excellence (NICE) [6,7], the European Society of Cariology
(ECS) [8], the American College of Cardiology/American Heart Association (ACC/AHA) [9] and
American Heart Association/American Stroke Association (AHA/ASA) [10].
In 2001, a fix-dose combination pill was proposed by the WHO[5] and was specified as a
combination of aspirin, beta-blocker, ACEI and statin. In 2003, Wald and Law proposed that a
fixed-dose combination pill, called polypill, consisting of a statin, BP-lowering agents, aspirin
and folic acid, could potentially reduce the risk of CVD by 80% in individuals from age 55[11].
Since the concept was presented, many research studies investigated the efficacy of different
medication combinations. A recent systematic review and meta-analysis summarized 13 ran-
domized controlled trials (RCTs) of different polypills with a total n = 9059, mainly conducted
in individuals with pre-existing atherosclerotic cardiovascular disease. The relatively short
duration of follow-up meant that there were no definitive conclusions possible supporting
mortality benefit of polypill from the RCT level evidence. [12]. The current RCTs focused on
comparison between polypill and usual care. There is still lack of RCT-level evidence on the
effectiveness of individual drug combinations. The existing evidence on individual drug com-
binations is from some previous observational studies, which have examined the impact of the
combination of antiplatelet agents, ACEIs/ARBs, beta-blockers and lipid-modifiers, called evi-
dence-based combination pharmacotherapy (EBCP) [13–17], but there has been no systematic
review to synthesize these together.
Uncertainties surrounding EBCP that have not yet been systematically assessed include: (i)
whether there is conclusive statistical evidence suggesting multi-drug treatments do better
than single-drug treatments for mortality benefit (ii) whether increasing the number of com-
ponents will confer additional benefits; and (iii) the role of each component of combination
therapy, and whether certain combinations have more potent mortality lowering effects. This
systematic review was conducted with a meta-analysis of existing observational studies that
investigated the impact of the EBCP on mortality and cardiovascular events in the secondary
prevention of CVD.
Methods
The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) state-
ment was used to guide the reporting of the methods and findings.[18,19]. A completed
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PRISMA checklist is provided as an additional file (S1 Appendix). The study protocol was reg-
istered in the International Prospective Register of Systematic Reviews database (PROSPERO:
CRD42018078069).
Systematic literature search
We performed the systematic literature search without limitations of language on EMBASE
(1980 to October 2018) and Medline (1946 to October 2018). The search strategies were devel-
oped based on the PICO (population, intervention, comparator and outcome) principle[20],
search terms (S2 Appendix) covering CVD (coronary heart disease (CHD) and stroke), cardio-
vascular drugs (lipid-modifiers, antiplatelet agents and first-line antihypertensive drugs) and
terms for combination therapy. We also examined the bibliographies of some relevant reviews
and articles to identify any additional studies.
Study selection
Three investigators (TTM, ZXW and LZ) independently screened studies to be included in the
review using predetermined inclusion criteria. Studies were included in the systematic review
if they: (i) included participants aged�18 years old with a history of coronary heart disease
(MI, stable or unstable angina pectoris), stroke or transient ischaemic attack (TIA); (ii) clearly
defined exposure to a combination pharmacotherapy including at least one antiplatelet agent,
one lipid-modifier and one drug of ACEI/ARB, beta-blockers or other commonly used cardio-
vascular drugs (diuretics, calcium channel blockers, α-adrenergic blockers, aldosterone antag-
onist, or renin inhibitor); (iii) clearly defined the outcome of all-cause mortality, major
cardiovascular events (fatal or non-fatal MI, angina, stroke or TIA); (iv) reported relative risk/
risk ratio (RR), hazard ratio (HR) or odds ratios (OR) or provided data for calculating the risk
estimates.
There was no restriction on sample size or language. Conference proceedings and abstracts
were excluded if there was insufficient data for determining the risk estimates and the 95%
confidence intervals (CI); or if they were not cohort or case-control studies.
Antiplatelet agents included: acetylsalicylic acid, adenosine reuptake inhibitors, adenosine
diphosphate receptor inhibitors, and P2Y12 antagonists. Lipid-modifiers consisted of all stat-
ins, bile acid sequestrants, ezetimibe, fibrates and nicotinic acid. Other commonly used cardio-
vascular drugs included thiazide-type diuretics, loop diuretics, aldosterone antagonists,
calcium channel blockers (CCBs), α-adrenergic blockers and renin inhibitors.
Appraisal of study quality
Two investigators (TTM and LQD) independently assessed the methodological quality of
included observational studies reviewing the study design, implementation, loss to follow-up,
exposure and outcome determination. We adapted the Newcastle-Ottawa Scale (NOS)[21] for
assessing the quality of the included studies. Separate NOS criteria were used for case-control
and cohort studies. Each version has eight items within three domains with a maximum of
nine stars (�): selection (representativeness), comparability (due to design or analysis), and
outcomes (assessment and follow-up). A study can receive one star for meeting each criterion,
while a maximum of two stars can be given for comparability (design or analysis). Studies with
one star for comparability only controlled for age and gender in the analysis whereas studies
with two stars under comparability also controlled for other important variables such as body
mass index, comorbidity, laboratory tests or use of other relevant drugs. A final score� seven
was considered as high quality[22].
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Data extraction and management
Authors TTM and LQD independently completed the data extraction form which was cross-
matched to ensure consistency and accuracy. Details of the study duration and design, sample
size and participant characteristics, study setting and data source, intervention(s) and outcome
(s) definitions, covariates from each of the included studies were extracted. Risk estimates in
the form of RR, OR or HR and their corresponding 95% CIs were used as a measure of the
association between intervention and outcome. For each study, we extracted the risk estimates
adjusted for the most number of confounding variables. For studies without an adjusted result,
the crude results were used for analysis.
Data analysis
The risk estimates of each observational study were pooled in the meta-analysis to obtain the
pooled RR. When a single study presented several risk estimates (i.e., separate estimates for the
combination of four and three drugs), we adjusted the pooled estimates for within-study corre-
lation. The inverse variance method with random effects models was used to calculate the
pooled RRs and 95% CIs[23].
Heterogeneity was assessed using the Cochran Q test and Higgins’ I2 statistic[19]. Galbraith
plot and subgroup analyses were carried out to investigate potential sources of heterogeneity
and conduct sensitivity analyses. Galbraith plot evaluates the weight of each study on the
meta-analysis by estimating the average RR and its contribution to the Q test[24]. In sensitivity
analyses, we excluded studies with high weight shown by Galbraith plot and repeated the ran-
dom-effects meta-analysis. Subgroup analyses were conducted to identify study-level heteroge-
neous factors, which included design (prospective cohort study, retrospective cohort study
and case-control study), diagnosis of CVD (CHD, acute coronary syndrome (ACS), MI and
stroke), age (<65 years, 65–75 years and>75 years), length of follow-up (<1 year, 1 year and
>1 year), study regions (Europe, Asia, North America, multi-regions) and different treatment
groups. All statistical analyses were performed using STATA version 15.0 and Revman version
5.3.
Results
Results from systematic literature search
A total of 10,970 records were exported from the literature research. Titles and abstracts were
screened and the full texts of 56 articles were further reviewed. 21 studies met the inclusion cri-
teria for this systematic review, involving 117,881 participants with CVD. Fig 1 shows our
search and selection process.
Characteristics and quality of included studies
Table 1 summarize the characteristics of the included studies. All studies were published in
English and from 2005 onwards: twelve were prospective cohort studies, six were retrospective
cohort studies[13–17,25–37], and three were case-control studies[38–40]. Twenty observa-
tional studies included were considered as high quality according to their NOS score� seven
(S2 and S3 Tables). The study of Timoteo et al.[32] was excluded due to the low quality with a
NOS score of five.
Mortality
We included seven cohort and two case-control studies that provided results from combina-
tions of EBCP and compared the risk of all-cause mortality with none or one component of
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EBCP in the primary meta-analysis (Fig 2). All the included studies presented a potential bene-
fit of combination therapy with a lower risk of all-cause mortality. The pooled RRs of cohort
and case-control studies were 0.55 (95% CI 0.47–0.64) and 0.68 (95% CI 0.62–0.75) respec-
tively. Overall, the use of combination therapy reduced the risk of all-cause mortality by 40%
(95% CI 34%-45%). In the study of Tay et al. [28], the outcomes were examined between youn-
ger patients (age < 75 years) and elderly patients separately. Younger patients benefited more
from combination therapy than elderly individuals.
Although we could not identify a statistically significant difference, the RRs of all-cause
mortality improved with each additional component of EBCP added: 0.67 (95% CI 0.60–0.76),
0.58 (95% CI 0.49–0.69) and 0.50 (95% CI 0.40–0.64) in patients with two, three and four com-
ponents respectively (Fig 3). Compared with suboptimal EBCP (less than 4 components), opti-
mal EBCP was associated with a lower risk of all-cause mortality by 19% (95% CI 15%-23%)
(Fig 4). The effects were similar in all patients with CHD (RR: 0.77, 95% CI 0.72–0.84), and
subgroups of: angina (RR: 0.79, 95% 0.65–0.96), MI (RR: 0.82, 95% CI 0.76–0.88), and acute
coronary syndromes 0.90 (95% CI 0.75–1.09) (Fig 4).
To assess the weight of each component of EBCP on outcomes, we evaluated pooled esti-
mate effects of combination therapy excluding any one component (Fig 5). The results show
that omitting any one component would reduce the potential beneficial effects of optimal
EBCP (RR: 0.53, 95% CI 0.42, 0.68). The changes were greatest when excluding antiplatelet
agents (RR: 0.80, 95% CI 0.72, 0.89). The difference was modest when omitting beta-blocker
(RR: 0.72, 95% CI 0.63, 0.82) and statins (RR: 0.70, 95% CI 0.63, 0.77). The change of pooled
estimate of omitting ACEI/ARB is shown to be inconspicuous (RR 0.60, 95% CI 0.51, 0.70).
Fig 1. PRISMA flow chart summarising study identification and selection.
https://doi.org/10.1371/journal.pone.0210988.g001
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Table 1. Characteristics of included studies.
Author,
year
Study design Country Inclusion
Criteria
No. of
Participants
Mean
Age ± SD
(Range)
Study
duration
Medications Exposure
ascertainment
Outcome
assessment
Al-Zakwani
2012
Prospective
cohort study
6 Middle
Eastern
countries
Consecutive
patients
hospitalized
with ACS
7567 56 ± 12 1 year Combination of
antiplatelet beta-
blocker, ACEI/ARB
and statin
Structured
interview;
discharge drugs
Telephone
interviews
Amann
2014
Prospective
cohort study
Germany Consecutive
patients
hospitalized for
an AMI
3844 62 (28–74) 6 years Combination of
antiplatelet beta-
blocker, ACEI/ARB
and statin
Structured
interview;
discharge drugs
German
population-based
AMI registry;
structured
interview
Bauer
2010
Prospective
cohort study
Germany Consecutive
hospital
survivors of
AMI
11823 Group 1:
71.1 (61.8–
79) Group
2: 65.0
(56.0–73.4)
1 year ASA, clopidogrel,
bata-blocker, ACEI/
ARB and statin
Structured
interview;
discharge drugs
Structured
interview
following
determined
criteria
Bezin
2017
Retrospective
cohort study
France Patients
hospitalised for
an ACS; aged
�20 years
2874 67 (56–77) 3.6 years
(2.2–5.3)
Bata-blockers,
antiplatelet agents,
statins and ACEI/
ARB
EGB database;
ATC code;
exposure defined
according to drug
dispensing in the
3-month period
following initial
ACS
EGB database;
ICD-10 cades
Bramlage
2010
Prospective
cohort study
Germany Consecutive
patients
hospitalized for
an AMI
5353 EBCP: 66.3
(56.9–75.1)
Sub-EBCP:
70.5 (60.9–
79.1)
1 year Combination of
ACEI/ARB, beta-
blocker, statins,
aspirin, clopidogrel
unless
contraindicated
Structured
interview;
secondary
prevention at
hospital
discharge
SAMI registry;
structured
interview
following
determined
criteria
Chen
2017
Retrospective
cohort study
China CAD patients 3176 EBCP: 64.4
Non-EBCP:
64.4
27.1
months
Combination of
antiplatelet agents,
statins, beta-blockers
and ACEI/ARB
Medical records;
discharge drugs
CAD database of
West China
hospital;
identified with
determined
criteria; followed
telephone or
hospital-visits
Danchin
2005
Prospective
cohort study
France Consecutive
patients with
AMI
2119 Triple
therapy: 71
(58–79)
Non-triple
therapy: 62
(51–72)
1 year Combination of
antiplatelet agents,
beta-blocker and
statins
Structured
interview;
discharge drugs
Structured
interview
Gouya
2007
Retrospective
cohort study
Austria Patients with
AMI
250 70 ± 14
(34–93)
552±200
days
ACEI/ARB, beta-
blockers, antiplatelet
agents and lipid-
lowering agents
BGKK database;
ATC codes;
discharge drugs
BGKK database;
ICD-9 codes
Gunnel
2013
Retrospective
cohort study
Australia Patients
hospitalized for
a first AMI
9580 Hierarchy 11 years Bata-blockers (BB),
statins (ST) and
ACEI/ARB
PBS register; PBS
item codes; drugs
received during
the 29-day
exposure period
post-discharge
for the primary
AMI
Hospital
morbidity data
collection;
Mortality
Register; ICD-9
codes
(Continued)
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Table 1. (Continued)
Author,
year
Study design Country Inclusion
Criteria
No. of
Participants
Mean
Age ± SD
(Range)
Study
duration
Medications Exposure
ascertainment
Outcome
assessment
Kopel
2014
Prospective
national
cohort study
USA Hospital
survivors of
ACS
9107 1 drug:
67 ± 14
2 drugs:
65 ± 14
3 drugs:
63 ± 13
4 drugs:
63 ± 12
1 year Antiplatelet, beta-
blockers, statins,
ACEI/ARB
Structured
interview;
discharge drugs
ACS Israeli
Survey; National
Population
Registry;
computerized
audit checks and
queries
Lafeber
2013
Prospective
cohort study
Netherlands Patients with
CAD
2706 60 ± 9 5.0 years
(2.4–10.2)
Aspirin, statins, BP-
lowering agents
Structured
interview
Structured
interview
Lee
2010
Prospective
cohort study
Korea Hospital
survivors of
AMI
9294 63.8 ± 12.5 180 ± 35
days
Combination of
antiplatelet agents,
statins, beta-blockers
and ACEI/ARB
Structured
interview;
discharge drugs
KAMIR registry;
medical records;
telephone
interview
Mukherjee
2004
Prospective
cohort study
USA Patients with
ACS
1358 63.7 ± 13.3 6 months Antiplatelet drugs,
BB, ACEI and lipid-
lowering agents
Structured
interview;
discharge drugs
Health system
record review or
phone call
interview
Park
2015
Retrospective
cohort study
USA,
Canada and
Scotland
Non-
cardioembolic
stroke patients
aged� 35 years
old
3680 Level 0:
63.3 ± 11.5
Level 1:
65.6 ± 12.5
Level 2:
67.2 ± 11.1
Level 3:
65.7 ± 10.2
2 years Antihypertensive
agents, lipid
modifiers and
antithrombotic
agents. Composite
appropriateness level:
level 0, none of the
indicated medications
prescribed; level 1, 1
medication
prescribed even
though 3 medications
indicated; level 2, 2
medications
prescribed even
though 2 medications
indicated; and level 3,
all indicated
medications were
prescribed.
Data from VISP
trial; structured
interview
Data from VISP
trial; structured
interview
Tay
2005
Prospective
cohort study
Singapore Consecutive
patients with
confirmed MI
5529 Young:
57 ± 10.7
Elderly:
81.42 ± 5.3
1 year Antiplatelet agents,
beta-blockers, ACEI/
ARB, lipid-lowering
agents
Structured
interview;
discharge drugs
Structured
interview
Timoteo
2006
Retrospective
cohort study
Portugal Consecutive
patients
hospitalized for
ACS
368 65 ± 13 30 days Antiplatelet agents,
beta-blockers, ACEI,
statins
Hospital clinical
data; drugs at
discharge or of
and event,
whichever
occurred first
Hospital clinical
data or telephone
contact
Yan
2007
Prospective
cohort study
Canada Patients with
ACS
5833 65 (55, 74) 1 year Combination of
antiplatelet/
anticoagulant, beta-
blocker, ACEI and
lipid-modifying
therapies
Structured
interview;
discharge drugs
Canadian ACS
Registry;
structured
interview;
telephone
interview
(Continued)
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Major cardiovascular events
Three studies reported a composite outcome of mortality and major non-fatal cardiovas-
cular events [16,25,27]. Compared with none or one component treatment, EBCP (>one
drug) was associated with a lower risk of the composite outcome (RR: 0.80, 95% CI 0.75–
0.85). Only Lafeber et al. reported the effect of combination therapy on the rate of vascular
mortality, with an RR of 0.70 (95% CI 0.62, 0.79) [25]. The pooled result of Lafeber et al.
[25], Kirchmayer et al. [39] and Van et al. [40] showed that combination treatment
decreased the risk of MI by 28% (95% CI 17%-38%). Regarding cerebrovascular events,
combination drug use also yielded a beneficial effect (RR: 0.79, 95% CI 0.68–0.91). In
summary, compared with none or one EBCP component, the use of combination therapy
reduced the relative risk of major cardiovascular events by 25% (95% CI 20%-30%) (Fig
6). Compared with suboptimal EBCP (less than 4 components), optimal EBCP was associ-
ated with a lower risk of cardiovascular events by 27% (95% CI 14%-21%) (Fig 7). The
results present that optimal EBCP reduced the risk of composite outcome by 14% (95% CI
11%-18%), vascular mortality by 27% (95% CI 22%-33%), MI by 16% (95% CI 10%-21%)
and cerebrovascular events by 19% (95% CI 9%-28%).
Table 1. (Continued)
Author,
year
Study design Country Inclusion
Criteria
No. of
Participants
Mean
Age ± SD
(Range)
Study
duration
Medications Exposure
ascertainment
Outcome
assessment
Zeymer
2011
Prospective
cohort study
Germany Patients with
AMI and
treated with a
beta-blocker at
discharge
9998 0–1 drug:
70.1 (60.3,
78.0)
2 drugs:
67.6 (58.2,
76.3) 3
drugs:
64.7(55.5,
73.0)
396 days Aspirin, ACEI and
statins
Structured
interview;
discharge drugs
ACOS registry;
structured
interview
Hippisley
2005
Nested case-
control study
UK Patients with a
fist diagnosis of
ischaemic heart
disease
13029 Cases: 80
(73, 86)
Controls:
80 (73, 85)
Cases:
20.3
months;
controls:
21.0
months
Different
combinations of
statins, aspirin, beta-
blocker and ACEI
Medical records QRESEARCH
database
Kirchmayer
2013
Nested case-
control study
Italy Patients with a
diagnosis of
AMI; aged 35–
100 years
6880 Women:
72.5 Men:
63.7
994.5
days
Combination of
antiplatelet agents,
beta-blockers, statins
and ACEI/ARB
Regional registry;
ACT
classification
system
Data from the
HIS; regional
MIS database;
ICD-9-CM codes
Van
2007
Nested case-
control study
Netherlands Patients with a
history of MI
3513 Cases: 66.8
Controls:
66.0
Cases:
32.6
months;
controls:
30.7
months
Different
combinations of
statins, antiplatelet
agents, beta-blocker
and ACEI
Medical records PHARMO
record linkage
system; ICD-
9-CM codes
Abbreviations: ACEI = angiotensin-converting enzyme inhibitor; ACOS = Acute Coronary Syndromes; ACS = acute coronary syndromes; AMI = acute myocardial
infarction; ARB = angiotensin receptor blocker; ASA = acetyl salicylic acid; ATC = the Anatomical Therapeutic Chemical; BGKK = Burgenla¨ndische
Gebietskrankenkasse; CAD = coronary artery disease; EBC = evidence-based component EGB = Echantillon Ge´ne´raliste de Be´ne´ficiaires; ICD = International
Classification of Disease; KAMIR = the Korea Acute Myocardial Infarction Registry; MI = myocardial infarction; No. = number; OMT = optimal medical therapy;
PBS = Pharmaveutical Benefits Scheme; SAMI = secondary prevention after acute myocardial infarction; SD = standard deviation; USA = the United States of America;
VISP = Vitamin Intervention for Stroke Prevention
https://doi.org/10.1371/journal.pone.0210988.t001
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Sensitivity analysis
The heterogeneity of the primary meta-analysis was high, with I2 = 87.9% (p< 0.001) (Fig 2).
In the Galbraith plot (S3 Fig), the study of Tay et al. [28] induced the highest heterogeneity, fol-
lowed by Hippisley et al. [38], Kirchmay et al. [39] and Yan et al. [30] We repeated the primary
meta-analysis with the random-effects model after excluding each of the four studies (S4
Table). Tay et al. [28] was shown to be the largest contributor to heterogeneity. When omitting
the study, I2 decreased to 72.1% though the pooled RR did not change remarkably (0.68, 95%
CI 0.67, 0.72).
We undertook subgroup analyses to examine the potential sources of heterogeneity related
to age, study regions, different diagnoses, length of follow-up and study designs on the EBCP’s
effect on all-cause mortality (S5 Table). The results show significant differences between sub-
groups in age (P < 0.05), region (P< 0.01), follow-up duration (P < 0.05) and study type
(P< 0.05), indicating the four covariates were likely to be associated with heterogeneity. Con-
versely, diagnosis of CVD, did not affect heterogeneity of the primary meta-analysis (P = 0.16).
The results of subgroups by age show that younger patients may benefit more from reductions
in all-cause mortality from EBCP than elderly individuals, with RRs of 0.44 (95% CI 0.30, 0.63)
in patients aged<65, and 0.71 (95% CI 0.65, 0.77) and 0.62 (95% CI 0.56, 0.69) for 65–75 and
>75 years old respectively. In terms of the subgroup analyses between different regions, the
relative risk of mortality was lower in Asian patients on EBCP (RR: 0.40, 96% CI 0.31, 0.53)
than patients in Europe (RR 0.67, 95% CI 0.63, 0.72), Canada/USA (RR 0.65, 95% CI 0.51,
0.83) or multi-region of USA, Canada and Scotland (RR 0.74, 95% CI 0.54, 1.01). Besides, the
differences between follow-up duration (RR:< 1 year: 0.57, 1 year: 0.52 and>1 year: 0.69) and
study types (RR: retrospective cohort study: 0.74, prospective cohort study: 0.54 and case-
Fig 2. Comparison: EBCP versus 0–1 EB component, Outcome: All-cause mortality.
https://doi.org/10.1371/journal.pone.0210988.g002
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control study: 0.68) were also presented to be related to the heterogeneity. In addition, we per-
formed another sensitivity analysis within studies which had the reference group of 0 EBCP
drug (S4 Fig). The results showed no significant different from the primary meta-analysis
(Fig 2).
Discussion
Our meta-analysis of observational studies assessed the effects of EBCP with antiplatelet drugs,
ACEIs/ARBs, beta-blockers, and lipid-modifiers on mortality and major cardiovascular events
in CVD patients. The results show a benefit for EBCP, suggesting an overall decrease in the
risk of all-cause mortality (approximately by 40%) and cardiovascular events (25%-30%) com-
pared to either monotherapy or no therapy.
In this systematic review, we examined the effects of increasing the number of components
of EBCP. The results show that each additional component of EBCP could confer a potential
8–9% survival benefit of patients with CVD with a median follow-up of one year. When
weighting the impact of each component, we found that antiplatelet agents made the greatest
contribution to the beneficial effects of combination therapy on survival in patients with CHD.
Excluding antiplatelet drugs from optimal EBCP decreased the beneficial effects by 27%. Our
results are supported by a meta-analysis of 193 RCTs. Based on 9,605 deaths, the study
reported that antiplatelet therapy produced a significant 15% reduction in vascular deaths
(P<0.0001) and about one-sixth of all-cause mortality (P<0.0001). The study also provided
strong evidence of benefit from antiplatelet therapy to major cardiovascular events (non-fatal
MI, non-fatal stroke or vascular death) [41].
Fig 3. Comparison: Combination therapy of different numbers of components versus 0–1 component, Outcome:
All-cause mortality.
https://doi.org/10.1371/journal.pone.0210988.g003
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Therefore, unless there are contraindications, antiplatelet agents should be considered as
the first component of EBCP in the secondary prevention of CHD.
The evidence available from the literature for beta blockers and statin therapy is equally as
strong. A meta-analysis of 147 RCTs suggested that beta-blockers could reduce CHD events by
29% (RR 0.71, 95% CI 0.66, 0.78). Additional RCT studies have also shown that beta-blockers
play an important role in reducing mortality and morbidity for up to a year after an MI [42]. A
meta-analysis of 14 RCTs of statins also demonstrated that statins could reduce the risk of all-
cause mortality by 12% and major vascular events by 21% [43]. Thus, beta-blockers and statins
count as valuable components of the optimal EBCP for CVD.
In our systematic review, we found a more modest effect for ACEI/ARB as part of EBCP. In
particular two studies have also shown that the inclusion of ACEI/ARB in combination with
statins, antiplatelet agents and beta-blockers was associated with a lower risk of mortality
[17,38].
In this systematic review, we found some research gaps in terms of EBCP in secondary pre-
vention of CVD.
Firstly, most studies included in the systematic review are based on CHD patients. Only the
study of Park et al. [27] was conducted in stroke patients. There is a paucity of evidence for the
benefit of EBCP in reducing the mortality risk in stroke patients, even though stroke represents
a significant proportion of all cardiovascular disease. Whilst co-morbidities and risk factors
cluster together, there is still a lack of data regarding any potential mortality benefit of ACEI
and beta-blocker in post-stroke patients who otherwise do not have an indication for their pre-
scription. This should be a priority area for further research.
Secondly, even though we did not limit any other conditions co-existing with CVD in the
study population, we could not find any studies specifically evaluating the effects of EBCP for
Fig 4. Comparison: EBCP versus sub-EBCP (< 4 components), Outcome: All-cause mortality.
https://doi.org/10.1371/journal.pone.0210988.g004
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secondary prevention of CVD in patients with comorbidities. Most of the studies included in
our review adjusted the risk estimates with comorbidities. Thus we were unable to identify if
the results are applicable equally in the presence of other conditions. Comorbidities are highly
prevalent in patients with CVD. A Dutch nationwide study found the percentage of patients
with comorbidity were 40% and 32% in coronary heart disease and cerebrovascular disease,
respectively [44]. In the context of clinical and functional heterogeneity, CVD patients with
different co-conditions may have different responses to pharmacotherapy. In addition, inter-
actions between cardiovascular drugs and treatment for comorbidities also need attention. For
example, some nonsteroidal anti-inflammatory drugs like ibuprofen and naproxen are known
to interfere with the antiplatelet effects of aspirin [45,46] as well as affect renal function and
hence handling of all components of EBCP, in particular ACEIs and ARBs.
Thirdly, most studies included in this systematic review only focused on the combination
of aspirin, clopidogrel, beta-blockers, ACEIs/ARBs and statins, observational evidence for the
combination of some other commonly used drugs is lacking. This may in part be due to a lack
of mortality benefit for many of these drugs tested in randomized trials (e.g. diuretics, CCBs
[47], and fibrates [48]), a lack of conclusive evidence of benefits for some drugs on the second-
ary prevention of CVD (e.g. spironolactone and eplerenone [49]), but may also be due to a
lack of follow-up time for newer medications that have come to market e.g. sacubitril/ valsar-
tan combination.
Finally, the length of follow-up in most of the included studies was less than one year, and
only effects of drugs in discharge were examined without considering other important long-
term effects. These include the possibility of sequential drug exchange or poor drug adherence.
Fig 5. Comparison: Combination excluding one component versus 0–1 EB component, Outcome: All-cause
mortality.
https://doi.org/10.1371/journal.pone.0210988.g005
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Only the study of Bezin et al. [16] reported the cumulated use of cardiovascular drugs, showing
a persistent benefit of combination therapy and additionally reductive effects on the occur-
rence of major adverse cardiac events or mortality when increasing the number of
components.
Strengths and limitations
In the absence of RCTs, we did the systematic review of observational studies. Our study has
several strengths. Firstly, we undertook extensive analysis in exploring potential variables that
could affect the effects of secondary prevention for CVD, hence providing clinicians with an
evidence base for their decision-making. Secondly, our results are robust and consistent, as
shown by our extensive analyses by using influence analysis, subgroup analysis and sensitivity
analysis.
There are some limitations in the current study. Firstly, the results of some subgroup analy-
ses were not credible enough because only one study was included. Secondly, differences in
study designs, exclusion criteria, control groups selection, duration of follow-up, exposure and
outcome definitions, including covariates and analyses models can affect the accuracy of
pooled estimates for both crude and adjusted RRs. Thirdly, several studies reported the esti-
mated effect sizes with HRs and ORs instead of RRs, and the exact statistical method was not
clearly described. We were not able to exclude the influence on results by combining these
three types of estimates in the meta-analysis. The variability between studies was unavoidable,
and the study conclusions should be evaluated alongside the reported heterogeneity. Neverthe-
less, we conducted sensitivity analyses to examine the impact of heterogeneity between studies
and assessed of the potential causes of heterogeneity. In addition, as studies included in each
Fig 6. Comparison: EBCP versus 0–1 EB component, Outcome: Major CV events.
https://doi.org/10.1371/journal.pone.0210988.g006
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meta-analysis were less than ten, we did not examine the publication bias [50,51]. Considering
all included studies reported a positive effect of combination therapy only with a difference in
the extent, therefore we think that important publication bias due to a preferential publication
of large studies with positive findings has not occurred.
Conclusions
In conclusion, our systematic review and meta-analysis suggest that in patients with CVD,
EBCP can reduce the risk of all-cause mortality by approximately 40% and major cardiovascu-
lar events by 25%-30%. Antiplatelet agents, beta-blockers and statins could be considered as
stable components of combination therapy in secondary prevention of CHD.
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